Skip to main content
letter
. 2022 May 18:NEJMc2205019. doi: 10.1056/NEJMc2205019

Figure 1. Neutralization of the BA.3 Omicron and Deltacron Variants.

Figure 1

Shown are neutralizing-antibody titers against virus pseudotyped with spike protein from ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) bearing the D614G mutation, along with the BA.3 and deltacron variants, in 10 serum samples obtained from health care workers who had received two doses of a messenger RNA (mRNA) vaccine (Panel A) and from the same workers after they had received three mRNA vaccine doses (Panel B). Also shown are neutralizing-antibody titers in samples obtained from 18 patients admitted to the intensive care unit (ICU) during the delta wave of the pandemic, including 12 unvaccinated patients (closed circles), 5 fully vaccinated patients (open circles), and 1 vaccinated and boosted patient (plus signs) (Panel C). In addition, neutralizing-antibody titers are shown for 31 patients who were hospitalized with Covid-19 but were not admitted to an ICU during the omicron wave of the pandemic, including 15 unvaccinated patients (closed circles), 8 fully vaccinated patients (open circles), and 8 vaccinated and boosted patients (plus signs) (Panel D). In all cases, geometric mean values for the 50% neutralization titers (NT50) are provided at the top of the plots along with the percentage of patients with neutralizing-antibody titers above the limit of detection (value of 80), as indicated by the dashed lines. 𝙸 bars represent 95% confidence intervals. Statistical significance was determined by one-way repeated-measures analysis of variance with Bonferroni’s multiple testing correction. NS denotes not significant.